Abstract Library

#2971 A Retrospective Multicentre Evaluation of the Outcomes and Management of Carcinoid Heart Disease in Patients with Advanced Midgut NETs: A NET-CONNECT Descriptive Study

Introduction: Carcinoid heart disease (CHD) is a poor prognostic factor in neuroendocrine tumours (NETs). However, the extreme variability of diagnostic and treatment approaches reported in literature account for uncertainties on the best management in this selected population.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Spada F

Authors: Spada F, Laskaratos F, Crona J, Oleinikov K, Zandee W,

Keywords: Carcinoid Heart Disease, NETs, Carcinoid Syndrome, Midgut NETs,

#2788 Favourable Outcome in Patients with Metastatic Pheochromocytomas and Paragangliomas Treated with 177Lu-DOTATATE

Introduction: There is limited previous data on Peptide receptor radiotherapy (PRRT) in pheochromocytoma (PCC) and paraganglioma (PGL).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Vyakaranam A

Authors: Vyakaranam A, Crona J, Thiis-Evensen E, Hellman P, Norlén O,

Keywords: PRRT, 177Lu-DOTATATE, Pheochromocytoma, Paraganglioma,

#2102 Pre-Treatment Tumor Growth Rate (TGR0) in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs) Treated with Systemic Therapies: Subgroup Analysis of the GREPONET Study

Introduction: TGR0 >4%/month was associated with shorter progression-free survival (PFS) in patients (pts) treated with lanreotide in the CLARINET study. Impact of TGR0 in pts treated with other systemic therapies (ST) and with Ki67>10% is unknown.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Crona J

Authors: Crona J, Lamarca A, Ronot M, Opalinska M, Lopez Lopez C,

Keywords: tumor growth rate, TGR, RECIST, Neuroendocrine Tumor,

#2053 Value of Tumor Growth Rate (TGR) as an Early Predictor of Patients’ Outcome in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs): The GREPONET Study

Introduction: TGR (% change in tumour volume per month (%/m)) is postulated to be an early radiological biomarker to overcome limitations of RECIST in NETs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Lamarca A

Authors: Lamarca A, Crona J, Ronot M, Opalinska M, Lopez Lopez C,

Keywords: tumor growth rate, response, progression-free survival, follow-up, neuroendocrine tumor, prognosis, TGR, RECIST, radiology,

#1523 Multiregion Analysis Reveal Evolutionary Patterns and a Chromosomal Instability Signature in Pancreatic Neuroendocrine Tumours

Introduction: Pancreatic neuroendocrine tumors (PNETs) are potentially lethal diseases that show variable degrees of proliferation and invasiveness. Although genetic subgroups have been suggested to give prognostic information the impact of clonal evolution to the development and outcome of PNETs remains unexplored.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Crona J

Authors: Crona J, Backman S, Kugelberg J, Maharjan R, Björklund P,

Keywords: Cancer evolution, Molecular genetics, Neuroendocrine Tumor,